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Edited by Maurice MontalAbstract Botulinum neurotoxins (BoNTs) inhibit neurotrans-
mitter release by selectively cleaving core components of the
vesicular fusion machinery. The synaptic vesicle proteins Synapt-
otagmin-I and -II act as receptors for BoNT/B and BoNT/G.
Here we show that BoNT/A also interacts with a synaptic vesicle
protein, the synaptic vesicle glycoprotein 2C (SV2C), but not
with the homologous proteins SV2A and SV2B. Binding of
BoNT/A occurs at the membrane juxtaposed region preceding
transmembrane domain 8. A peptide comprising the intravesicu-
lar domain between transmembrane domains 7 and 8 speciﬁ-
cally reduces the neurotoxicity of BoNT/A at phrenic nerve
preparations demonstrating the physiological relevance of this
interaction.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The seven serotypes of botulinum neurotoxins (BoNTs) are
extremely potent bacterial protein toxins that provoke the
disease botulism which is characterised by ﬂaccid paralysis.
Each neurotoxin is composed of four domains. Their amino-
terminal domain, the light chain (LC), acts as Zn2+ dependent
endopeptidase to speciﬁcally hydrolyse certain soluble
N-ethlymaleimide sensitive attachment protein receptors of
the vesicular fusion machinery. This results in disruption of
the Ca2+ triggered fusion of synaptic vesicles with the presyn-
aptic membrane (reviewed in [1]). Their heavy chain (HC),
which is tethered to the LC via a single disulphide bond, is
responsible for delivering the catalytic domain to its site of ac-
tion, the cytosol of neural cells. This mission is accomplished
by the carboxyl-terminal segment of HC, the HC-fragment
(HC), which comprises two domains, HCN and HCC, and the
amino-terminal half of HC, the HN domain. HC binds withAbbreviations: BoNT, botulinum neurotoxin; HC, heavy chain; HC,
carboxyl-terminal half of HC; HN, amino-terminal half of HC; LC,
light chain; SV2, synaptic vesicle glycoprotein 2; Syt, synaptotagmin;
Syp, synaptophysin; Syo, Synaptoporin; Syg, Synaptogyrin
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doi:10.1016/j.febslet.2006.02.074extraordinary speciﬁcity to nerve terminals at the neuromuscu-
lar junction, whereas the HN domain, following receptor med-
iated endocytosis and intracellular transport to the endosomal
compartment, translocates the LC across the vesicular mem-
brane into the cytosol.
Current use of BoNTs as pharmaceutical underlies the
importance of deﬁning their speciﬁc receptors on nerve termi-
nals. It has long been known that polysialogangliosides, i.e.,
glycosphingolipids that are particularly enriched in the outer
leaﬂet of neural cell membranes, are crucial for the adherence
of BoNTs to neurons [2]. However, protein receptors appear to
be involved as well. Consequently, a two-receptor model was
proposed [3]. This predicts that the abundant polysialoganglio-
sides trap and accumulate BoNTs in the plane of the plasma
membrane, where they linger until acquiring contact with their
sparsely occurring protein receptor. To account for the ob-
served accelerated uptake of BoNTs [4,5] and the earlier onset
of the blockade of neurotransmission in response to nerve
stimulation [6,7], proteins that mediate the internalisation of
BoNTs should be integral constituents of synaptic vesicles. It
is likely that the intravesicular parts of these proteins are only
temporarily exposed upon fusion of synaptic vesicles at the
synaptic cleft. For example, BoNT/B and BoNT/G use as their
receptors the intravesicular parts of Synaptotagmin (Syt)-I and
Syt-II [7–9], two proteins that link membrane fusion to Ca2+
entry [10–13]. Protein receptors for the remaining BoNTs are
currently unknown.
In the present study, we investigated whether intravesicular
parts of synaptic vesicle proteins could serve as protein recep-
tors for BoNTs. Our results establish that BoNT/A directly
interacts with the large intravesicular domain of the synaptic
vesicle glycoprotein 2C (SV2C), but not with the correspond-
ing region of the homologous SV2A and SV2B proteins. The
large intravesicular domain of SV2C drastically reduced the
toxicity of BoNT/A at mice phrenic nerve preparations demon-
strating the physiological relevance of this major vesicular pro-
tein for the activity of BoNT/A, the main BoNT employed in
current medicine.2. Materials and methods
2.1. Plasmid constructions and production of proteins
Production and puriﬁcation of full-length BoNT/A and BoNT/B,
the HC-fragments of BoNT/A, B, C, D, E, F, and G carrying a car-
boxyl-terminal StrepTag as well as GST-Syt-II-1–90 were previously
described [9,14].blished by Elsevier B.V. All rights reserved.
Fig. 1. The cell binding HC-fragment of BoNT/A interacts with SV2C.
(A) Schematic drawing of SV2. SV2s are predicted to comprise 12
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tic vesicle proteins were cloned in pGEX-4T3 using suitable oligonucle-
otides and a mouse embryonic cDNA library (GST-Syo-157–218,
GST-Syg-I-45–98) or plasmids containing appropriate cDNA as tem-
plates: GST-Syg-I-127–169 (RZPD, Deutsches Ressourcenzentrum
fu¨r Genomforschung GmbH; www.rzpd.de; ID IRAKp961C072Q),
GST-SV2A-468–618 (RZPD-ID IRAKp961O24100Q), GST-Syo-22–
103 (rat; T. C. Su¨dhof, Dallas), GST-Syg-III-46–88 and GST-Syg-
III-128–168 (mouse; T. C. Su¨dhof, Dallas), GST-SV2B-413–560 (rat;
S. Bajjalieh, Seattle), and GST-SV2C-454–603 (rat; R. Janz, Houston).
A plasmid encoding GST-SV2-C/A comprising amino acids 454–553 of
SV2C and 568–594 of SV2A was constructed by PCR using suitable
oligonucleotides. Nucleotide sequences of all plasmids were veriﬁed
by DNA sequencing.
GST-fusion-proteins were produced in E. coli BL21 and puriﬁed
employing glutathione–Sepharose-4B matrix (Amersham Biosciences,
Freiburg, Germany). Proteins used for GST-pull-down experiments
were prepared in 20 mM Tris–HCl, 150 mM NaCl, pH 7.4 supple-
mented with 0.5% Triton X-100 (Tris/NaCl/Triton buﬀer). Proteins
tested as inhibitors in mouse phrenic nerve preparations were dialysed
against Krebs-Ringer buﬀer (118 mM NaCl, 4.7 mM KCl, 1.2 mM
MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, 2.5 mM CaCl2, 11 mM
glucose). Radiolabelled HC-fragments were synthesised in vitro from
pSP72 derivatives that were previously linearised downstream of the
neurotoxins’ carboxyl-terminal codon using the reticulocyte lysate sys-
tem (Promega, Mannheim, Germany) and L-35S-methionine (840 kBq,
>37 TBq/mmol; Amersham Biosciences), in a total volume of 25 ll.
2.2. GST-pull-down assays
GST-fusion-proteins (150 pmol each) immobilised to 10 ll of gluta-
thione–Sepharose-4B matrix were incubated with recombinant
HC-fragments (100 pmol each) or in vitro translated radiolabelled
HC-fragments in a total volume of 100 ll Tris/NaCl/Triton buﬀer for
3 h at 4 C. Beads were collected by centrifugation and washed three
times each with 160 ll Tris/NaCl/Triton buﬀer. Washed pellet fractions
were boiled in sample buﬀer (60 mM Tris–HCl, pH 6.75, 5% b-mercap-
toethanol, 2% sodium dodecyl sulfate, 10% glycerol, 0.007% bromphe-
nol blue), analysed by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, and HC-fragments were subsequently detected by Coo-
massie blue staining, immunoblotting using a polyclonal anti StrepTag
serum (IBA GmbH, Go¨ttingen, Germany), or phosphorimaging.
2.3. Mouse phrenic nerve assays
The assay was set up as described earlier [15]. Electrical stimulation
of the phrenic nerve was performed continuously at a frequency of
1 Hz. Isometric contractions were recorded with a force transducer
and analysed with the VitroDat Online software (FMI GmbH, See-
heim-Ober Beerbach, Germany). The time required to reduce the con-
traction amplitude to 50% of the starting value (paralytic half-time)
was determined. Recombinant single chain BoNT/A was applied in
triplicates at ﬁnal concentrations of 24.3, 72.8, 223, and 728 pM. A
concentration–response-curve could be described by the power func-
tion y(A) = 225.87x0.2573 (R2 = 0.9627). A concentration–response-
curve described by the power function y(B) = 423.59x0.297
(R2 = 0.983) was obtained in the same manner for recombinant single
chain BoNT/B applying ﬁnal concentrations of 100, 300, 1000, and
3000 pM. For inhibition studies single chain BoNT/A (223 pM) and
BoNT/B (1000 pM) were mixed with GST-SV2C-454–579 or GST-
SV2-C/A at 4.7 or 11.2 lM concentrations, incubated for 15 min at
room temperature and subsequently added to the hemi-diaphragm
preparation. The resulting paralytic half-times were converted to cor-
relative concentrations using the respective equations mentioned
above. Toxicities were calculated as the ratio of derived and applied
toxin concentrations, and were ﬁnally expressed as percentage of the
respective untreated toxin. Individual inhibition experiments were con-
ducted three to nine times.transmembrane domains and one large intravesicular domain. Num-
bers specify amino acid positions of the isoform SV2C. GST-SV2
constructs used in GST-pull-down experiments contained the entire
intravesicular domain plus the adjacent downstream transmembrane
domain 8. (B, C) GST-fusion-proteins immobilised on glutathione–
Sepharose beads were incubated with recombinant (B) or 35S-labelled
(C) BoNT HC-fragments in the presence of gangliosides. Proteins
bound to the solid phase were visualised by Coomassie blue staining
(B) or phosphorimaging (C). b points towards bound BoNT/A HC.3. Results and discussion
3.1. Speciﬁc interaction of BoNT/A with SV2C
To address whether transmembranous synaptic vesicle pro-
teins serve as receptors for BoNT/A, C, D, E and F, we ana-lysed binding of BoNT HC-fragments to intravesicular
domains of synaptic vesicle proteins in vitro by GST-pull-
down experiments. Potential targets were selected on the basis
that their intravesicular segments exceeded 20 amino acids in
size and comprised both intravesicular segments of the tetra-
spanin proteins Synaptophysin (Syp), Synaptoporin (Syo),
Synaptogyrin (Syg)-I, and Syg-III, as well as the large intrave-
sicular domain of the SV2 isoforms A, B, and C (see Fig. 1A).
These segments together with their adjacent carboxyl-terminal
transmembrane domain were puriﬁed as GST-fusion-proteins
and assembled in mixed Triton X-100-ganglioside micelles.
The Syt binding BoNT/B and G HC-fragments were used as
controls in these experiments. Of the proteins analysed only
GST-SV2C-454–603 was capable of pulling down an HC-frag-
ment, BoNT/A HC. Neither BoNT/E and BoNT/F, which are
the nearest relatives of BoNT/A regarding the cell binding HC-
fragment, nor BoNT/B, C, D, and G interacted with any of
these proteins (Fig. 1B or data not shown). The speciﬁcity of
the newly discovered BoNT/A-SV2C interaction was corrobo-
rated by corresponding experiments employing 35S-labelled
HC-fragments that lack aﬃnity tags. Again binding was only
observed between SV2C and BoNT/A HC (see Fig. 1C). This
interaction was not markedly altered in the absence of ganglio-
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(data not shown; [9]).
3.2. BoNT/A binds the juxtamembrane segment of SV2C
BoNT/B and BoNT/G were recently demonstrated to adhere
to the membrane juxtaposed region of Syt [7,9]. This may
probably be important to assure the approach of the neuro-
toxin to the protein receptor on the cell surface while it is still
attached to the ganglioside receptor. Therefore, we investi-
gated next whether BoNT/A associates with the corresponding
region of SV2C. Carboxyl-terminally truncated versions of the
large intravesicular domain of SV2C were generated as GST-
fusion-proteins and checked for binding. The results depicted
in Fig. 2 show that BoNT/A HC binds to GST-SV2C-454–
603 and GST-SV2C-454–579, the latter one just lacking the
transmembrane domain, but not to any further truncated
SV2C variant. This ﬁnding supports that BoNT/A like
BoNT/B and BoNT/G requires the membrane juxtaposed seg-
ment of its receptor protein and suggests that this binding
mode may be a general principle valid for all BoNTs. To ex-
clude the possibility that carboxyl-terminal deletions had de-
stroyed the structure and thereby caused the failure of
BoNT/A binding, we constructed a hybrid intravesicular do-
main peptide of SV2 in which the carboxyl-terminal 26 amino
acids of SV2C were replaced with the homologous residues of
SV2A (38% identical residues; GST-SV2-C/A). As at least part
of the proposed binding site is altered, GST-SV2-C/A did not
interact with BoNT/A HC (see Fig. 2) supporting the data ob-
tained with the deletion constructs. Amino-terminally trun-
cated SV2C intravesicular domain segments were not
obtainable from E. coli lysates probably because these trunca-Fig. 2. BoNT/A HC interacts with the intravesicular region juxtaposed
to transmembrane domain 8 of SV2C. GST-fusion-proteins immobi-
lised on glutathione–Sepharose beads were incubated with BoNT/A
and B HC-fragments in the presence of gangliosides. Upper panels:
BoNT HC-fragments were detected by a polyclonal antiserum directed
against their StrepTag. Lower panel: Coomassie blue staining of GST-
fusion-protein input. * marks full-length GST-fusion-proteins.tions interfere with formation of the native structure of the
intravesicular domain [16,17].
3.3. Inhibition of BoNT/A activity by SV2C at the phrenic nerve
In order to demonstrate the physiological relevance of the
newly discovered BoNT/A-SV2C interaction for the activity
of the neurotoxin, we investigated whether the neurotoxicity
of BoNT/A could be blocked in the presence of the large intra-
vesicular domain of SV2C. The mouse hemi-diaphragm was
chosen for these experiments as it is innervated by cholinergic
synapses, the natural sites of BoNT action. In the ﬁrst experi-
ment, BoNT/A was applied alone in a concentration of
0.22 nM. This resulted in a 50% reduction of the hemi-dia-
phragm muscle contractile force within 50 ± 7 min (paralytic
half-time). The presence of 4.7 lM GST-SV2C-454–579 pro-
longed the paralytic half-time of BoNT/A to 72 ± 3 min which
corresponds to 75% inhibition of the neurotoxicity. Increasing
the concentration to 11.2 lM extended the paralytic half-time
to 83 ± 8 min equivalent to 85% inhibition of the neurotoxicity
(see Fig. 3). This inhibitory potency of GST-SV2C-454–579
was speciﬁc for BoNT/A, as the same bath concentrations of
the fusion protein did not result in a signiﬁcant prolongation
of the paralytic half-time of BoNT/B (see Fig. 3), which evi-
dently does not interact with SV2C.
In order to further document the speciﬁcity of the inhibition
experiment we tested the inhibitory potency of GST-SV2-C/A
hybrid. In line with the results of the GST-pull-down experi-
ments the hybrid molecule had no inﬂuence on the neurotox-
icity of BoNT/A. The paralytic half-times remained at 51 ± 4
or 51 ± 5min in the presence of 4.7 or 11.2 lMGST-SV2-C/A,
respectively, and were thus similar to the untreated control.
This result and the inability of the intravesicular domain of
Syt-II to impair the toxicity of BoNT/A [9] demonstrate, in a
physiological test system, that inhibition through GST-SV2C
is speciﬁc and does not interfere with other physiologicalFig. 3. The large intravesicular domain of SV2C drastically reduces
the activity of BoNT/A at the mouse phrenic nerve. BoNT/A and
BoNT/B were preincubated for 15 min at room temperature with GST-
SV2C-454–579 or GST-SV2-C/A hybrid, as indicated. Mixtures were
then added to electrically stimulated mice hemi-diaphragm prepara-
tions and isometric contractions were recorded and analysed. The time
required to decrease the amplitude to 50% of the starting value
(paralytic half-time) was determined as well as remaining toxicity
versus the respective untreated neurotoxin. Data are means ± S.D.
(n = 3–9).
2014 S. Mahrhold et al. / FEBS Letters 580 (2006) 2011–2014processes in the assay system. Together, these ﬁndings evidence
that the carboxyl-terminal portion of the large intravesicular
domain of SV2C mediates the entry of BoNT/A into periphe-
ral neural cells.
SV2 family of integral synaptic vesicle proteins seem to reg-
ulate Ca2+-dependent exocytosis in neurons and neuroendo-
crine cells [18,19]. Interestingly, certain parts of SV2 and
another BoNT receptor, Syt, can interact with each other
[20,21]. Since Syt is also important in calcium-dependent vesi-
cle exocytosis, it is conceivable that BoNTs, as a general rule,
employ protein receptors that have one task in the vesicle path-
way – regulation of vesicle fusion.
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